Amgen Inc and Kyowa Kirin Co Ltd Collaboration on KHK4083 and LUMAKRAS FDA Approval Conference Call Transcript
My name is Crystal, and I will be your conference facilitator today for Amgen's conference call on the approval of LUMAKRAS and the collaboration with Kyowa Kirin. (Operator Instructions)
I would now like to introduce Arvind Sood, Vice President of Investor Relations. Mr. Sood, you may begin.
Crystal, thank you. Good morning, everyone. Thanks for joining us this morning for this call. We have not 1, but 2 topics to discuss today. You may have seen this morning that we announced an agreement to jointly develop and commercialize a novel molecule for atopic dermatitis. We had set up this call initially, of course, to discuss the approval of LUMAKRAS, our first-in-class KRAS G12C inhibitor.
So to discuss these topics further, I'm joined today by Peter Griffith, our CFO; Dave Reese, our Head of R&D; and Murdo Gordon, our Head of Global Commercial Operations. Each will make brief prepared comments, and we shall have plenty of time for Q&A.
So with that, I would like to turn the call over to Peter
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
